Summary

Transcatheter aortic valve implantation (TAVI) is the recommended treatment for “inoperable” patients with severe aortic stenosis, based on the 1-year results of the PARTNER trial [NCT00530894; Leon MB et al. N Engl J Med 2010]. The objective of this PARTNER trial analysis was to evaluate the clinical outcomes of TAVI compared with standard therapy at 2 years in patients with inoperable AS [PARTNER Cohort B].